Szingapúr - angol - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - human normal immunoglobulin - infusion, solution - 50 mg/ml - human normal immunoglobulin 50 mg/ml

Szingapúr - angol - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - human antihepatitis b immunoglobulin - injection, solution - 250 i.u./ml - human antihepatitis b immunoglobulin 250 i.u./ml

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 4000 mg - liquid, multipurpose - excipient ingredients: monobasic sodium phosphate monohydrate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1- antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 500 mg - liquid, multipurpose - excipient ingredients: monobasic sodium phosphate monohydrate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1- antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

Írország - angol - HPRA (Health Products Regulatory Authority)

grifols deutschland gmbh - human alpha1-proteinase inhibitor - powder and solvent for solution for infusion - alfa1 antitrypsin

Írország - angol - HPRA (Health Products Regulatory Authority)

grifols deutschland gmbh - human alpha1-proteinase inhibitor - powder and solvent for solution for infusion - alfa1 antitrypsin

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 1000 mg - solution - excipient ingredients: monobasic sodium phosphate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1-antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

Panama - angol - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

instituto grifols, s.a. - albÚmina humana - albÚmina humana.... 0.2 g

Szaúd-Arábia - angol - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

instituto grifols, spain - albumin human - solution - 20 %

Szaúd-Arábia - angol - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

instituto grifols, s.a, spain - coagulation factor ix recombinant human - powder for solution for injection - 40-62.5 iu/ml